Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.

"Declaration of personal interests: WJ Sandborn has received grant support, personal fees and non‐financial support from Pfizer Inc during the conduct of the study; research support from AbbVie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Pfizer Inc, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda and Theravance Biopharma; consultancy fees from AbbVie, Abivax, AdMIRx, Alfasigma, Alimentiv (Robarts Clinical Trials, owned by Health Academic Research Trust [HART]), Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health (Salix), BeiGene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol‐Myers Squibb, Celgene, Celltrion, Cellularity, Cosmo Pharmaceuticals, Equillium, Escalier Biosciences, Forbion, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pandion Therapeutics, Pfizer Inc, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals, Tillotts Pharma, UCB, Vedanta Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, Vivreon Biosciences and Zealand Pharma; and has stock or stock options in Allakos, BeiGene, Gossamer Bio, Oppilan Pharma, Progenity, Prometheus Biosciences, Shoreline Biosciences, Ventyx Biosciences and Vimalan Biosciences. WJ Sandborn’s spouse has received consultancy fees from Iveric Bio and Oppilan Pharma; is an employee of Prometheus Biosciences; and has stock or stock options in Iveric Bio, Oppilan Pharma Progenity, Prometheus Biosciences, Ventyx Biosciences and Vimalan Biosciences. N Lawendy, C Su, DT Judd, X Guo, I Modesto and W Wang are all employees and stockholders of Pfizer Inc. S Danese has received consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead Sciences, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, Pfizer Inc, Roche, Sandoz, Takeda, TiGenix, UCB and Vifor. EV Loftus Jr. has received research support from AbbVie, Amgen, Bristol‐Myers Squibb, Celgene, Genentech, Gilead Sciences, Janssen, Pfizer Inc, Receptos, Robarts Clinical Trials, Takeda, Theravance and UCB; and consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Bristol‐Myers Squibb, Boehringer Ingelheim, Calibr, Celgene, Lilly, Genentech, Gilead Sciences, Gossamer Bio, Iterative Scopes, Janssen, Lilly, Ono Pharma, Pfizer Inc, Sun Pharma, Takeda and UCB. A Hart has received consultancy fees from AbbVie, Allergan, Atlantic, Bristol‐Myers Squibb, Celltrion, Falk Pharma, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer Inc, Pharmacosmos, Shire and Takeda; lecture fees from AbbVie, Atlantic, Bristol‐Myers Squibb, Celltrion, Falk Pharma, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer Inc, Pharmacosmos, Shire and Takeda; other fees from Genentech (Global Steering Committee); and has served as an advisory board member for AbbVie, Atlantic, Bristol‐Myers Squibb, Celltrion, Falk Pharma, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer Inc, Pharmacosmos, Shire and Takeda. I Dotan has received personal fees from AbbVie, Abbott, Altman Research, Arena Pharmaceuticals, Athos, Cambridge Healthcare, Celgene/Bristol‐Myers Squibb, Celltrion, DSM, Falk Pharma, Ferring, Food Industries Organisation, Genentech/Roche, Gilead Sciences, Janssen, MSD, Neopharm, Nestlé, Pfizer Inc, Rafa Laboratories, Sandoz, Sangamo, Sublimity, Takeda and Wildbio. AOMC Damião has received personal fees from AbbVie, Ferring, Janssen, Takeda and Pfizer Inc. J Panés has received research support from AbbVie and Pfizer Inc; and personal fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Celltrion, F. Hoffmann‐La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Immunic, Janssen, Origo, Pandion, Pfizer Inc, Progenity, Robarts Clinical Trials, Takeda, Theravance and Wassermann."

"Funding information"